As Dr. Robert Califf takes the helm at the U.S. Food and Drug Administration (FDA), he has several urgent priorities including managing and evolving the agency's response to the COVID-19 pandemic. Alongside this task, he should be strengthening FDA's ability to respond to future pandemics – and he has a timely opportunity to do just that within this year's reauthorization of the Prescription Drug User Fee Act (PDUFA).